PATENT CLAIM ANALYSIS

Application Number: 16151730
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "298000"]

Abstract:
This invention relates to the use of low doses of (+)-α-dihydrotetrabenazine for the treatment of movement disorders, such as Tourette's syndrome.

Claim (Index 1):
A method of treating a subject suffering from a movement disorder; which method comprises administering to the subject a therapeutically effective amount of a VMAT2 blocking compound so as to provide in the subject a therapeutically effective level of VMAT2 blocking; said VMAT2 blocking being maintained such that there is at least 30% VMAT2 blocking after a period of 6.5 hours from administration of the VMAT2 blocking compound; wherein:\n the VMAT2 blocking compound is (+)-\u03b1-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof; the administration of the therapeutically effective amount of the VMAT2 blocking compound takes place within an initial time window of 30 minutes, and no further administration of the VMAT2 blocking compound takes place within the period of 6.5 hours; the said therapeutically effective amount is no more than 8 mg of (+)-\u03b1-dihydrotetrabenazine free base or an equimolar amount of a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15939826', '15939837', '12555695', '15116786', '14442996']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8257367829240913
- 35 USC 102 Novelty (BERT): 0.5884355571630149
- Combined Prediction Score: 0.8020066603479836
- Mean Citation Score: 432.914024
- Max Citation Score: 644.5441
- Similarity Product: 393.0832418868184

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test